Prosecution Insights
Last updated: May 29, 2026
Application No. 18/069,621

CIRCULAR RNA COMPOSITIONS AND METHODS

Final Rejection §112
Filed
Dec 21, 2022
Priority
May 22, 2019 — provisional 62/851,548 +9 more
Examiner
BURKHART, MICHAEL D
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Orna Therapeutics Inc.
OA Round
2 (Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
511 granted / 819 resolved
+2.4% vs TC avg
Moderate +11% lift
Without
With
+10.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
32 currently pending
Career history
863
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
35.1%
-4.9% vs TC avg
§102
10.7%
-29.3% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 819 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt and entry of the response dated 9/9/2025 is acknowledged. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1,3-4,6-10,15-20 and 22-25are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is maintained for reasons made of record in the Office Action dated 6/18/2025 and for reasons set forth below. Response to Arguments Applicant's arguments filed 9/9/2025 have been fully considered but they are not persuasive. Applicants essentially assert that: 1) the instant specification provides over 1,900 species of ionizable lipids; 2) US Patent 11,802,144, issued from application 17/384,460 to which the instant application claims priority, includes similar claims with a generic recitation to a transfer vehicle comprising “… an ionizable lipid…”. Regarding 1), although this assertion may be true, the claims are not directed to ionizable lipids alone, rather, the claims require such lipids to form a transfer vehicle having the function of “delivering the circular RNA polynucleotide” as also recited in the claims. This is the focus of the instant rejection and is not addressed by applicants. Applicants response does not address the shortcomings of the instant specification regarding this structure/function relationship required by the instant claims. Regarding 2), each application is treated on its own merits. The prosecution of application ’460 is thus not binding to the instant application. Further, the issued claims do not attempt to claim the transfer vehicle with negative limitations regarding the ionizable lipid, i.e. they do not attempt to define such lipids by reciting what they are not. It is noted that the ionizable lipids excluded by the instant claims, but included in the ‘144 claims, include species taught by the relevant art and the instant specification to provide the claimed function of delivering nucleic acids in the context of a transfer vehicle. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Burkhart whose telephone number is (571)272-2915. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL D BURKHART/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Dec 21, 2022
Application Filed
Jun 18, 2025
Non-Final Rejection mailed — §112
Sep 09, 2025
Response Filed
Dec 17, 2025
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637497
AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
4y 7m to grant Granted May 26, 2026
Patent 12600796
NOVEL CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS
4y 7m to grant Granted Apr 14, 2026
Patent 12595460
Method and Apparatus for Producing CAR T Cells
1y 1m to grant Granted Apr 07, 2026
Patent 12590148
METHODS FOR THE SIMULTANEOUS EXPANSION OF MULTIPLE IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES OF SAME IN CANCER IMMUNOTHERAPY
4y 11m to grant Granted Mar 31, 2026
Patent 12577546
PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
4y 11m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
73%
With Interview (+10.9%)
3y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 819 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month